33.31
price up icon0.60%   0.20
pre-market  시장 영업 전:  32.81   -0.50   -1.50%
loading
전일 마감가:
$33.11
열려 있는:
$32.98
하루 거래량:
737.02K
Relative Volume:
0.77
시가총액:
$2.93B
수익:
$4.72M
순이익/손실:
$-277.91M
주가수익비율:
-8.9303
EPS:
-3.73
순현금흐름:
$-203.56M
1주 성능:
+6.52%
1개월 성능:
-4.09%
6개월 성능:
-40.79%
1년 성능:
-24.30%
1일 변동 폭
Value
$32.20
$33.59
1주일 범위
Value
$31.68
$33.59
52주 변동 폭
Value
$24.10
$62.53

Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile

Name
명칭
Crinetics Pharmaceuticals Inc
Name
전화
858-450-6464
Name
주소
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA
Name
직원
437
Name
트위터
@Crinetics
Name
다음 수익 날짜
2024-11-12
Name
최신 SEC 제출 서류
Name
CRNX's Discussions on Twitter

CRNX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
CRNX
Crinetics Pharmaceuticals Inc
33.31 2.93B 4.72M -277.91M -203.56M -3.73
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
503.50 126.09B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
568.91 64.01B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
629.51 36.63B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
257.19 30.64B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.77 27.24B 3.81B -644.79M -669.77M -6.24

Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-25 개시 Stifel Buy
2025-02-11 개시 TD Cowen Buy
2025-02-04 개시 Wolfe Research Peer Perform
2025-01-22 업그레이드 Jefferies Hold → Buy
2024-03-06 개시 Citigroup Buy
2024-01-16 개시 Morgan Stanley Overweight
2023-12-21 개시 Jefferies Hold
2023-11-20 재개 JP Morgan Overweight
2023-10-24 재개 Cantor Fitzgerald Overweight
2023-08-31 개시 Oppenheimer Outperform
2023-04-24 개시 Piper Sandler Overweight
2023-03-30 개시 Robert W. Baird Outperform
2021-11-30 개시 JMP Securities Mkt Outperform
2021-11-23 개시 Evercore ISI Outperform
2021-06-18 업그레이드 JP Morgan Neutral → Overweight
2019-12-23 개시 ROTH Capital Buy
2019-02-14 개시 H.C. Wainwright Buy
2018-08-13 개시 JP Morgan Neutral
2018-08-13 개시 Leerink Partners Outperform
2018-08-13 개시 Piper Jaffray Overweight
모두보기

Crinetics Pharmaceuticals Inc 주식(CRNX)의 최신 뉴스

pulisher
Apr 28, 2025

LPL Financial LLC Acquires 1,162 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Apr 28, 2025
pulisher
Apr 25, 2025

Market Watch Highlights: Crinetics Pharmaceuticals Inc (CRNX) Ends on an Upturn Note at 33.39 - DWinneX

Apr 25, 2025
pulisher
Apr 25, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock Holdings Boosted by Envestnet Asset Management Inc. - Defense World

Apr 25, 2025
pulisher
Apr 23, 2025

Are Crinetics Pharmaceuticals Inc (CRNX) shares a good deal now? - uspostnews.com

Apr 23, 2025
pulisher
Apr 22, 2025

CRNX stock touches 52-week low at $35.47 amid market shifts - MSN

Apr 22, 2025
pulisher
Apr 22, 2025

Crinetics Pharmaceuticals patents new SSTR3 agonists - BioWorld MedTech

Apr 22, 2025
pulisher
Apr 21, 2025

Wells Fargo & Company MN Increases Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Apr 21, 2025
pulisher
Apr 21, 2025

Invesco Ltd. Acquires 42,954 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Apr 21, 2025
pulisher
Apr 20, 2025

Russell Investments Group Ltd. Sells 43,501 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Apr 20, 2025
pulisher
Apr 17, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Affinity Asset Advisors LLC - MarketBeat

Apr 17, 2025
pulisher
Apr 14, 2025

Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Unloaded Rep. Josh Gottheimer - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Alliancebernstein L.P. - Defense World

Apr 13, 2025
pulisher
Apr 13, 2025

JPMorgan Chase & Co. Has $13.78 Million Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Apr 13, 2025
pulisher
Apr 13, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 | CRNX Stock News - GuruFocus

Apr 12, 2025
pulisher
Apr 11, 2025

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 - The Manila Times

Apr 11, 2025
pulisher
Apr 11, 2025

Key Investor Alert: Crinetics Sets Date for Crucial Q1 2025 Financial Results - Stock Titan

Apr 11, 2025
pulisher
Apr 10, 2025

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

Apr 10, 2025
pulisher
Apr 10, 2025

Acromegaly Pipeline 2025: Detailed Clinical Trials - openPR.com

Apr 10, 2025
pulisher
Apr 10, 2025

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 10, 2025
pulisher
Apr 07, 2025

Stock Surge: Crinetics Pharmaceuticals Inc (CRNX) Closes at 26.89, Marking a -6.86 Increase/Decrease - DWinneX

Apr 07, 2025
pulisher
Apr 05, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Sei Investments Co. - Defense World

Apr 05, 2025
pulisher
Apr 02, 2025

Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA - Seeking Alpha

Apr 02, 2025
pulisher
Mar 31, 2025

CRNX stock touches 52-week low at $31.81 amid market challenges - Investing.com

Mar 31, 2025
pulisher
Mar 27, 2025

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation Of Marketing Authorization Application (MAA) And Orphan Drug Designation (ODD) For Paltusotine In Acromegaly - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Breakthrough: First Oral Acromegaly Drug Hits Major EU Milestone with Dual Regulatory Wins - Stock Titan

Mar 27, 2025
pulisher
Mar 26, 2025

Crinetics Pharmaceuticals (NASDAQ:CRNX) Now Covered by Stifel Nicolaus - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

Stifel Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Buy Recommendation - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

Stifel Initiates Crinetics Pharmaceuticals at Buy With $60 Price Target - Marketscreener.com

Mar 25, 2025
pulisher
Mar 25, 2025

Taking a Closer Look At Crinetics Pharmaceuticals Inc (CRNX) Following Its Recent Trade - knoxdaily.com

Mar 25, 2025
pulisher
Mar 24, 2025

Cushing's Syndrome Pipeline 2025: Therapies, MOA Insights, - openPR.com

Mar 24, 2025
pulisher
Mar 24, 2025

(CRNX) Trading Report - news.stocktradersdaily.com

Mar 24, 2025
pulisher
Mar 24, 2025

Connor Clark & Lunn Investment Management Ltd. Sells 13,735 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

Proficio Capital Partners LLC Purchases Shares of 14,674 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

Crinetics Pharmaceuticals COO Jeff Knight sells $244,963 in stock By Investing.com - Investing.com Australia

Mar 22, 2025
pulisher
Mar 22, 2025

Zurcher Kantonalbank Zurich Cantonalbank Purchases 2,970 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - The AM Reporter

Mar 22, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals’ chief med and dev officer sells $86,020 in stock - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Stock: Executives Sell Shares Amid Analyst Optimism - sharewise.com

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals’ chief med and dev officer sells $86,020 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals CEO Richard Struthers sells shares worth $592,016 By Investing.com - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals COO Jeff Knight sells $244,963 in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals chief scientific officer sells $197,352 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals CEO Richard Struthers sells shares worth $592,016 - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals chief scientific officer sells $197,352 in stock - Investing.com

Mar 21, 2025
pulisher
Mar 19, 2025

CRNX News Today | Why did Crinetics Pharmaceuticals stock go down today? - MarketBeat

Mar 19, 2025
pulisher
Mar 19, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Mar 19, 2025
pulisher
Mar 16, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Charles Schwab Investment Management Inc. - Defense World

Mar 16, 2025

Crinetics Pharmaceuticals Inc (CRNX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.79
price up icon 0.78%
$71.40
price up icon 2.20%
$32.71
price up icon 0.52%
$23.62
price down icon 2.03%
$104.00
price up icon 0.00%
biotechnology ONC
$249.77
price up icon 0.12%
자본화:     |  볼륨(24시간):